García GRJ, Sánchez MMA, Cerda GP, Torreblanca MM, Aguirre SJS, Martínez SJ

Language: Spanish
References: 13
Page: 55-60
PDF size: 71.29 Kb.

ABSTRACT

Objective: To assess levosimendan efficacy in acute cardiac failure. Methods: We included 25 patients with acute cardiac failure and partial conventional therapy response defined as persistence of low cardiac output with inotropic support. We started levosimendan at loading dose and continuous infusion for 24 hours, recording hemodynamic data, as well as clinical variables. Results: All patients showed clinical and hemodynamic improvement. Pulmonary wedge capillary pressure (PWCP) decreased from 18 cmH₂O (11-30 cmH₂O) to 14 cmH₂O (8-15 cmH₂O) at 12 hours (p = 0.3) and to 13 cmH₂O (8-12 cmH₂O) at the end of the infusion period (p = 0.2). Cardiac index increased from 2.1 L/min/m² (1.8-3.5 L/min/m²) to 2.86 L/min/m² (2-4.3 L/min/m²) at 12 hours (p = 0.03) and to 3.08 L/min/m² at the end of the infusion period (p = 0.02). Tachycardia higher than 120 bpm was present in six patients. No major hypotensive events were present. Mortality to the present is of eight patients. Conclusion: Levosimendan infusion improved hemodynamics and clinical variables in acute cardiac failure with few side effects in this small series of patients.

REFERENCES

1. Follath JG, Cleland F, Just JG, Papp Y, Scholoz H, Peuhkurinern K, et al: Efficacy and of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202.

2. Greenberg B, Borghi C, Perrone S: Pharmacotherapeutic approaches for decompensated heart failure: role for the calcium sensitizer levosimendan? Eur J Heart Failure 2003; 5(1): 13-21.

3. Thackray S, Eastaugh J, Freemantle N, Cieland JGF: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with Heart failure: a meta-regression analysis. Eur J Heart Failure 2002; 4(4): 515-529.

4. Felker M, O’connor M: Inotropic therapy for Heart failure: An evidence-based approach. Am Heart J 2001; 142: 393-401

5. Masao E: Regulation of myocardial contractility by a downstream mechanism. Circ Res 1998; 83: 230-232.

6. Cleland JGF, McGowan J: Levosimendan: a new era for inodilatador therapy for heart failure. Curr Opin Cardiology 2002; 17: 257-265.

7. Nieminen MS, Akkila J, Hasenfuss G: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-12.

8. Slawsky MT, Colucci WS, Gotlieb SS, Greenberg BH, Haeusslein E, Hare J, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222-2227.

9. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81-89.

10. Moiseyev VS, Poder P, Andrejevs N, Rhuda MY, Golicov AP, Lazebnik LB, et al: RUSSIAN investigators: Randomize study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarction. Eur Heart J 2002; 23(18): 1422-1432.

11. Cleland JG, Takala A, Apajasalo M, Zethraerus N, Kobelt G: Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low output heart failure: an analysis based on the international LIDO trial. Eur J Heart Failure 2003; 5(1): 101-108.

12. Lilleberg J, Nieminem S, Akkila J, Kuitunen A, Lehtonen L, Verkkala K, et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow an myocardial substrate utilization early after coronary artery bypass grafting. Eur J Heart Failure 1998; 19(4): 660-668.

13. Greenberg B, Borghi C, Perrone S: Pharmacotherapeutic approaches for decompensated heart failure: role for the calcium sensitizer levosimendan? Eur J Heart Failure 2003; 5(1): 13-21.